Article

Genetic Changes in Squamous Cell Lung Cancer A Review

Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer (Impact Factor: 5.8). 05/2012; 7(5):924-33. DOI: 10.1097/JTO.0b013e31824cc334
Source: PubMed

ABSTRACT Identifying specific somatic mutations that drive tumor growth has transformed the treatment of lung cancer. For example, cancers with sensitizing epidermal growth factor receptor mutations and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase translocations can have remarkable responses to epidermal growth factor receptor and ALK inhibitors respectively, leading to significant clinical benefit. However, effective molecularly targeted therapies have disproportionately impacted adenocarcinomas compared to squamous cell carcinomas, and never or light smokers compared to heavy smokers. Further progress in non-small-cell lung cancer will require the identification and effective targeting of molecular alterations in all subtypes of lung cancer. Here, we review the current knowledge about the molecular alterations found in squamous cell carcinoma of the lung. First, we will discuss the ongoing efforts to comprehensively assess the squamous cell carcinoma genome. We will then discuss the evidence supporting the role of specific genes in driving squamous cell carcinomas. By describing the landscape of somatic targets in squamous cell lung cancer, we hope to crystallize the current understanding of potential targets, spur development of therapies that can have clinical impact, and underscore the importance of new discoveries in this field.

2 Followers
 · 
267 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is the leading cause of cancer-related death worldwide, and squamous cell carcinoma is the second most frequent histological subtype. The improvement registered in the last years in the treatment of non-small cell lung cancer is attributable in part to the concept of personalized therapy, and to the possibility to transfer biological discoveries into clinical practice. Major changes have mainly characterized the adenocarcinoma histology, with the detection of the EGFR mutation and the EML4-ALK translocation, targeted by specific tyrosine kinase inhibitors. Despite its interesting oncogenic profile, squamous carcinoma is not the most appropriate example of "druggable disease", as it is characterized by deplorable results, often with a huge toxicity profile and without any benefit in terms of overall survival. At the present time, cytotoxic drugs are still the only treatment options for patients with advanced squamous cell carcinoma. Recent advances in the molecular characterization of squamous carcinoma have identified mutations and alterations, and clinical trials are ongoing to target these changes.
    03/2012; 2(1). DOI:10.1007/s13665-012-0034-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is the leading cause of death by cancer worldwide. The vast majority of lung tumors are non-small cell lung carcinomas (NSCLC), and surgical resection remains the only effective treatment. According to the new WHO histological classification of lung cancer, NSCLC comprise three major histological subgroups; squamous cell carcinoma, adenocarcinoma, and large cell carcinoma and its variants. The recent discovery of EGFR tyrosine kinase inhibitor-sensitive mutations in a subset of adenocarcinomas has raised hopes toward the identification of new druggable molecular alterations in all subtypes of NSCLC.
    Oncologie 09/2012; 14(9). DOI:10.1007/s10269-012-2206-1 · 0.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lungenkarzinome gehören zu den häufigsten bösartigen Tumorerkrankungen der westlichen Welt. Sie sind mit einem weiten Spektrum von Mutationen assoziiert, die vor allem Gene therapierelevanter Signalwege betreffen. Aufgrund der wachsenden Zahl an genetischen Loci, die für eine verbesserte Einordnung der Lungenkarzinome untersucht werden müssen, sind neue, hocheffiziente Ansätze einer weiter reichenden Mutationsanalyse gefragt. Umfangreiche Mutationsanalysen progressions- und therapierelevanter Gene können durch die neuen Sequenzierformen sog. „Next-generation-sequencing“ (NGS)-Ansätze angegangen werden, da diese aufgrund besonders hoher Sequenzierkapazitäten die Möglichkeit bieten, eine Vielzahl von Genen hochauflösend zu untersuchen. Für molekularpathologische Untersuchungen stehen zurzeit im Wesentlichen drei Plattformen zur Verfügung, die die parallele Sequenzierung von multiplen Genen und Proben in einem Sequenziergang ermöglichen: die 454- oder Pyrosequenzierung, die synthesebasierte Sequenzierung und die Halbleitersequenzierung, in der die Protonenabgabe beim Nukelotideinbau gemessen wird. Das Prinzip, dass nach klonaler Expansion einzelner DNA-Moleküle sequenziert wird, erlaubt nicht nur Angaben zur Allelfrequenz und zur Mutationsrate, sondern bietet auch sehr hohe Empfindlichkeiten in der Detektion von niedrigfrequenten Varianten.
    Der Pathologe 02/2013; 34(1). DOI:10.1007/s00292-012-1704-7 · 0.64 Impact Factor

Preview

Download
3 Downloads
Available from